Travere Therapeutics (TVTX) reported $74.79 million in revenue for the quarter ended December 2024, representing a year-over-year increase of 66$0.73 for the same period compares to -$1.16 a year ago.The reported revenue compares to the Zacks Consensus Estimate of$73.44 million, representing a surprise of +1.84%. The company delivered an EPS surprise of -25.86%, with the consensus EPS estimate being -$0.58.While investors scrutinize revenue and earnings changes year-over-year and how they compar ...